Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin + Nirogacestat in NDMM
NCT05573802Phase 2Recruiting
- Sponsor
- Hellenic Society of Hematology
- Start
- Jul 2023
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of belantamab mafodotin in multiple myeloma (MM) (3 arms), sponsored by Hellenic Society of Hematology. Primary endpoints: Dose-Limiting Toxicity up to 28 days, Adverse Events up to 4 years and 2 more. Started Jul 2023; status: recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05573802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05573802.